Stratification of patients is the way to go to develop neuroprotective/ disease-modifying drugs for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 15, Issue 2, 2008, Pages 339-345

  Iqbal, Khalid ^a   Chohan, M Omar ^a   Grundke Iqbal, Inge ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Alzheimer's disease; Alzheimer's disease subgroups; Amyloid ; Lewy bodies; Neurofibrillary pathology; Tau; Tauopathies; Ubiquitin

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; HUMAN; LEWY BODY; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY;

EID: 54249113234     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-15215     Document Type: Review

References (31)

1. Anonymous, Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiol Aging 19 (1998), 109-116.
2. J.D. Best, M.T. Jay, F. Otu, I. Churcher, M. Reilly, P. Morentin-Gutierrez, C. Pattison, T. Harrison, M.S. Shearman and J.R. Atack, In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4- (2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) in the rat, J Pharmacol Exp Ther 317 (2006), 786-790.
3. K. Buerger, M. Ewers, T. Pirttila, R. Zinkowski, I. Alafuzoff, S.J. Teipel, J. DeBernardis, D. Kerkman, C. McCulloch, H. Soininen and H. Hampel, CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease, Brain 129 (2006), 3035-3041.
4. D. Campion, C. Dumanchin, D. Hannequin, B. Dubois, S. Belliard, M. Puel, C. Thomas-Anterion, A. Michon, C. Martin, F. Charbonnier, G. Raux, A. Camuzat, C. Penet, V. Mesnage, M. Martinez, F. Clerget-Darpoux, A. Brice and T. Frebourg, Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum, Am J Hum Genet 65 (1999), 664-670.
5. S. Chalbot, K. Blennow, I. Grundke-Iqbal and K. Iqbal, CSF phospholipase A2 activity is a biomarker of blood brain barrier permeability but not Alzheimer's Disease, 11th International Conference on Alzheimer's Disease & Related Disorders (2008), in press.
6. M.O. Chohan, S. Khatoon, I. Grundke-Iqbal and K. Iqbal, Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine, FEBS Lett 580 (2006), 3973-3979.
7. C.M. Clark, S. Xie, J. Chittams, D. Ewbank, E. Peskind, D. Galasko, J.C. Morris, D.W. McKeel, Jr., M. Farlow, S.L. Weitlauf, J. Quinn, J. Kaye, D. Knopman, H. Arai, R.S. Doody, C. DeCarli, S. Leight, V.M. Lee and J.Q. Trojanowski, Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?, Arch Neurol 60 (2003), 1696-1702.
8. M. El Mouedden, M. Vandermeeren, T. Meert and M. Mercken, Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors, Curr Pharm Des 12 (2006), 671-676.
9. A.M. Fagan, M.A. Mintun, R.H. Mach, S.Y. Lee, C.S. Dence, A.R. Shah, G.N. LaRossa, M.L. Spinner, W.E. Klunk, C.A. Mathis, S.T. DeKosky, J.C. Morris and D.M. Holtzman, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann Neurol 59 (2006), 512-519.
10. G.G. Glenner and C.W. Wong, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun 120 (1984), 885-890.
11. G.G. Glenner, C.W. Wong, V. Quaranta and E.D. Eanes, The amyloid deposits in Alzheimer's disease: their nature and pathogenesis, Appl Pathol 2 (1984), 357-369.
12. C.X. Gong, T.J. Singh, I. Grundke-Iqbal and K. Iqbal, Phosphoprotein phosphatase activities in Alzheimer disease brain, J Neurochem 61 (1993), 921-927.
13. I. Grundke-Iqbal, K. Iqbal, M. Quinlan, Y.C. Tung, M.S. Zaidi and H.M. Wisniewski, Microtubule-associated protein tau. A component of Alzheimer paired helical filaments, J Biol Chem 261 (1986), 6084-6089.
14. I. Grundke-Iqbal, K. Iqbal, Y.C. Tung, M. Quinlan, H.M. Wisniewski and L.I. Binder, Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc Natl Acad Sci USA 83 (1986), 4913-4917.
15. M. Gunnarsson, L. Kilander, J. Sudelof, H. Basun and L. Lannfelt, Reduction of hyperphosphorylated tau during memantine treatment of Alzheimer's disease., Alzheimers Dementia 2 (2006), S63-S64.
16. D.P. Hanger, H.L. Byers, S. Wray, K.Y. Leung, M.J. Saxton, A. Seereeram, C.H. Reynolds, M.A. Ward and B.H. Anderton, Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis, J Biol Chem 282 (2007), 23645-23654.
17. K. Iqbal, C. Alonso Adel, S. Chen, M.O. Chohan, E. El-Akkad, C.X. Gong, S. Khatoon, B. Li, F. Liu, A. Rahman, H. Tanimukai and I. Grundke-Iqbal, Tau pathology in Alzheimer disease and other tauopathies, Biochim Biophys Acta 1739 (2005), 198-210.
18. K. Iqbal, M. Flory, S. Khatoon, H. Soininen, T. Pirttila, M. Lehtovirta, I. Alafuzoff, K. Blennow, N. Andreasen, E. Vanmechelen and I. Grundke-Iqbal, Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers, Ann Neurol 58 (2005), 748-757.
19. K. Iqbal and I. Grundke-Iqbal, Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies, Acta Neuropathol (Berl) 109 (2005), 25-31.
20. G.B. Karas, P. Scheltens, S.A. Rombouts, P.J. Visser, R.A. van Schijndel, N.C. Fox and F. Barkhof, Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease, Neuroimage 23 (2004), 708-716.
21. M. Kim, L.B. Hersh, M.A. Leissring, M. Ingelsson, T. Matsui, W. Farris, A. Lu, B.T. Hyman, D.J. Selkoe, L. Bertram and R.E. Tanzi, Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families, J Biol Chem 282 (2007), 7825-7832.
22. L. Li, A. Sengupta, N. Haque, I. Grundke-Iqbal and K. Iqbal, Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration, FEBS Lett 566 (2004), 261-269.
23. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34 (1984), 939-944.
24. D.L. Miller, I.A. Papayannopoulos, J. Styles, S.A. Bobin, Y.Y. Lin, K. Biemann and K. Iqbal, Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease, Arch Biochem Biophys 301 (1993), 41-52.
25. T. Mizutani and M. Kasahara, Hippocampal atrophy secondary to entorhinal cortical degeneration in Alzheimer-type dementia, Neurosci Lett 222 (1997), 119-122.
26. T. Mizutani, M. Sakata, M. Enemoto and S.Yamada, Pathological heterogeneity of Alzheimer type dementia, in: Alzheimer Disease: Biology, Diagnosis and Therapeutics, (Vol. 33), K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H.M. Wisniewski, eds, John Wiley & Sons Ltd., Chichester, UK, 1997, pp. 247-255.
27. A.D. Roses, On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease, J Alzheimers Dis 9 (2006), 361-366.
28. T.C. Saido and N. Iwata, Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy, Neurosci Res 54 (2006), 235-253.
29. J.M. Schott, S.L. Price, C. Frost, J.L. Whitwell, M.N. Rossor and N.C. Fox, Measuring atrophy in Alzheimer diseaseL a serial MRI study over 6 and 12 months., Neurology 65 (2005), 119-124.
30. J.Z. Wang, I. Grundke-Iqbal and K. Iqbal, Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration, Eur J Neurosci 25 (2007), 59-68.
31. F.P. Zemlan, W.S. Rosenberg, P.A. Luebbe, T.A. Campbell, G.E. Dean, N.E. Weiner, J.A. Cohen, R.A. Rudick and D. Woo, Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins, J Neurochem 72 (1999), 741-750.